These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29683008)

  • 1. First trimester combined screening biochemistry in detection of congenital heart defects.
    Alanen J; Korpimaki T; Kouru H; Sairanen M; Leskinen M; Gissler M; Ryynanen M; Nevalainen J
    J Matern Fetal Neonatal Med; 2019 Oct; 32(19):3272-3277. PubMed ID: 29683008
    [No Abstract]   [Full Text] [Related]  

  • 2. A prospective cohort study on association of first-trimester serum biomarkers and risk of isolated foetal congenital heart defects.
    Hematian MN; Hessami K; Torabi S; Saleh M; Nouri B; Saleh M
    Biomarkers; 2021 Dec; 26(8):747-751. PubMed ID: 34645361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
    Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
    Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
    Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
    Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
    Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
    Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study.
    Crossley JA; Aitken DA; Cameron AD; McBride E; Connor JM
    BJOG; 2002 Jun; 109(6):667-76. PubMed ID: 12118646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fetal nuchal translucency in severe congenital heart defects: experiences in Northern Finland.
    Alanen J; Leskinen M; Sairanen M; Korpimaki T; Kouru H; Gissler M; Ryynanen M; Nevalainen J
    J Matern Fetal Neonatal Med; 2019 May; 32(9):1454-1460. PubMed ID: 29157037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First trimester fetal ultrasound parameters associated with PAPP-A and fβ-hCG.
    Papastefanou I; Souka A; Eleuftheriades M; Pilalis A; Kassanos D
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1029-33. PubMed ID: 21988784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a 'vanishing twin' on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology.
    Gjerris AC; Loft A; Pinborg A; Christiansen M; Tabor A
    Hum Reprod; 2009 Jan; 24(1):55-62. PubMed ID: 18835870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K; Bindra R; Cacho AM; Nicolaides KH
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
    Spencer K
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased time-to-pregnancy and first trimester Down's syndrome screening.
    Ranta JK; Raatikainen K; Romppanen J; Pulkki K; Heinonen S
    Hum Reprod; 2010 Feb; 25(2):412-7. PubMed ID: 19945962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.